Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model

Cabozantinib (CBZ) is a small molecule tyrosine kinase receptor inhibitor, which could also inhibit the ABCG2 transporter function. Therefore, CBZ could re-sensitize cancer cells that are resistant to ABCG2 substrate drugs including topotecan (TPT). However, its reversal effect against TPT resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Zi-Ning, Teng, Qiu-Xu, Gupta, Pranav, Zhang, Wei, Narayanan, Silpa, Yang, Dong-Hua, Wurpel, John N. D., Fan, Ying-Fang, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019832/
https://www.ncbi.nlm.nih.gov/pubmed/33829017
http://dx.doi.org/10.3389/fcell.2021.640957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019832/
https://www.ncbi.nlm.nih.gov/pubmed/33829017
http://dx.doi.org/10.3389/fcell.2021.640957

Ejemplares similares